These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 15384929)

  • 1. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.
    Shackleton M; Davis ID; Hopkins W; Jackson H; Dimopoulos N; Tai T; Chen Q; Parente P; Jefford M; Masterman KA; Caron D; Chen W; Maraskovsky E; Cebon J
    Cancer Immun; 2004 Sep; 4():9. PubMed ID: 15384929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant.
    Adams S; O'Neill DW; Nonaka D; Hardin E; Chiriboga L; Siu K; Cruz CM; Angiulli A; Angiulli F; Ritter E; Holman RM; Shapiro RL; Berman RS; Berner N; Shao Y; Manches O; Pan L; Venhaus RR; Hoffman EW; Jungbluth A; Gnjatic S; Old L; Pavlick AC; Bhardwaj N
    J Immunol; 2008 Jul; 181(1):776-84. PubMed ID: 18566444
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.
    Valmori D; Dutoit V; Ayyoub M; Rimoldi D; Guillaume P; Liénard D; Lejeune F; Cerottini JC; Romero P; Speiser DE
    Cancer Immun; 2003 Oct; 3():15. PubMed ID: 14580186
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
    J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients.
    Goldinger SM; Dummer R; Baumgaertner P; Mihic-Probst D; Schwarz K; Hammann-Haenni A; Willers J; Geldhof C; Prior JO; Kündig TM; Michielin O; Bachmann MF; Speiser DE
    Eur J Immunol; 2012 Nov; 42(11):3049-61. PubMed ID: 22806397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients.
    Bonehill A; Van Nuffel AM; Corthals J; Tuyaerts S; Heirman C; François V; Colau D; van der Bruggen P; Neyns B; Thielemans K
    Clin Cancer Res; 2009 May; 15(10):3366-75. PubMed ID: 19417017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients.
    de Vries IJ; Lesterhuis WJ; Scharenborg NM; Engelen LP; Ruiter DJ; Gerritsen MJ; Croockewit S; Britten CM; Torensma R; Adema GJ; Figdor CG; Punt CJ
    Clin Cancer Res; 2003 Nov; 9(14):5091-100. PubMed ID: 14613986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
    Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma.
    Hersey P; Menzies SW; Halliday GM; Nguyen T; Farrelly ML; DeSilva C; Lett M
    Cancer Immunol Immunother; 2004 Feb; 53(2):125-34. PubMed ID: 14600790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical rather than intradermal application of the TLR7 ligand imiquimod leads to human dermal dendritic cell maturation and CD8+ T-cell cross-priming.
    Fehres CM; Bruijns SC; van Beelen AJ; Kalay H; Ambrosini M; Hooijberg E; Unger WW; de Gruijl TD; van Kooyk Y
    Eur J Immunol; 2014 Aug; 44(8):2415-24. PubMed ID: 24825342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of T-cell responses in metastatic melanoma patients vaccinated with dendritic cells pulsed with tumor lysates.
    Griffioen M; Borghi M; Schrier PI; Osanto S; Schadendorf D
    Cancer Immunol Immunother; 2004 Aug; 53(8):715-22. PubMed ID: 14997347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases.
    Mauldin IS; Wages NA; Stowman AM; Wang E; Olson WC; Deacon DH; Smith KT; Galeassi N; Teague JE; Smolkin ME; Chianese-Bullock KA; Clark RA; Petroni GR; Marincola FM; Mullins DW; Slingluff CL
    Cancer Immunol Immunother; 2016 Oct; 65(10):1201-12. PubMed ID: 27522582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.
    Sabado RL; Pavlick A; Gnjatic S; Cruz CM; Vengco I; Hasan F; Spadaccia M; Darvishian F; Chiriboga L; Holman RM; Escalon J; Muren C; Escano C; Yepes E; Sharpe D; Vasilakos JP; Rolnitzsky L; Goldberg J; Mandeli J; Adams S; Jungbluth A; Pan L; Venhaus R; Ott PA; Bhardwaj N
    Cancer Immunol Res; 2015 Mar; 3(3):278-287. PubMed ID: 25633712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma.
    Pavlick A; Blazquez AB; Meseck M; Lattanzi M; Ott PA; Marron TU; Holman RM; Mandeli J; Salazar AM; McClain CB; Gimenez G; Balan S; Gnjatic S; Sabado RL; Bhardwaj N
    Cancer Immunol Res; 2020 Jan; 8(1):70-80. PubMed ID: 31699709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HLA-independent heterogeneity of CD8+ T cell responses to MAGE-3, Melan-A/MART-1, gp100, tyrosinase, MC1R, and TRP-2 in vaccine-treated melanoma patients.
    Reynolds SR; Celis E; Sette A; Oratz R; Shapiro RL; Johnston D; Fotino M; Bystryn JC
    J Immunol; 1998 Dec; 161(12):6970-6. PubMed ID: 9862732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flt3 ligand as a vaccine adjuvant in association with HER-2/neu peptide-based vaccines in patients with HER-2/neu-overexpressing cancers.
    Disis ML; Rinn K; Knutson KL; Davis D; Caron D; dela Rosa C; Schiffman K
    Blood; 2002 Apr; 99(8):2845-50. PubMed ID: 11929774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single injection of CD34+ progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma.
    Palucka AK; Dhodapkar MV; Paczesny S; Burkeholder S; Wittkowski KM; Steinman RM; Fay J; Banchereau J
    J Immunother; 2003; 26(5):432-9. PubMed ID: 12973032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma.
    Butterfield LH; Comin-Anduix B; Vujanovic L; Lee Y; Dissette VB; Yang JQ; Vu HT; Seja E; Oseguera DK; Potter DM; Glaspy JA; Economou JS; Ribas A
    J Immunother; 2008 Apr; 31(3):294-309. PubMed ID: 18317358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
    Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
    J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial.
    Oshita C; Takikawa M; Kume A; Miyata H; Ashizawa T; Iizuka A; Kiyohara Y; Yoshikawa S; Tanosaki R; Yamazaki N; Yamamoto A; Takesako K; Yamaguchi K; Akiyama Y
    Oncol Rep; 2012 Oct; 28(4):1131-8. PubMed ID: 22895835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.